Potent A2A and A2B adenosine receptor partial agonist ( Ki = 2.6 nM and EC50 = 12 nM respectively). Also exhibits selectivity for A1 over A3 (Ki values are 2.6 and 538 nM respectively).
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 348.38. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.87 mL||14.35 mL||28.7 mL|
|5 mM||0.57 mL||2.87 mL||5.74 mL|
|10 mM||0.29 mL||1.44 mL||2.87 mL|
|50 mM||0.06 mL||0.29 mL||0.57 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Beukers et al (2004) New, non-adenosine, high potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine J.Med.Chem 47 3707 PMID: 15239649
Lane et al (2012) A novel nonribose agonist, LUF5834, engages residues that are distinct from those of adenosine-like ligands to activate the adenosine A2a receptor Mol.Pharmacol. 81 475 PMID: 22188926
If you know of a relevant reference for LUF 5834, please let us know.
View Related Products by Product Action
Keywords: LUF 5834, supplier, LUF5834, potent, A2A, A2B, adenosine, receptors, agonists, Adenosine, A2A, Receptors, Tocris Bioscience
Citations for LUF 5834
Citations are publications that use Tocris products.
Currently there are no citations for LUF 5834. Do you know of a great paper that uses LUF 5834 from Tocris? If so please let us know.
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.